A Meta-Analysis on the Effect and Safety of LCZ696 in the Treatment of Hypertension

Table 2

Adverse events (AEs) reported in the incorporated studies.

AEs	No. of studies (n)	LCZ696 group, n/n	ARBs group, n/n	Heterogeneity	Analysis model	OR	95% CI
All AEs	8	802/2396	612/1917	= 0.5, I^2 = 0	Fixed-effect model	1.13	0.99, 1.29	0.08
Discontinuations because of AEs	4	29/1865	24/1389	= 0.58, I^2 = 0	Fixed-effect model	1.09	0.62, 1.90	0.77
Serious AEs	5	37/1721	28/1245	= 0.38, I^2 = 5%	Fixed-effect model	1.14	0.69, 1.88	0.6
Dizziness	8	46/2396	27/1917	= 0.28, I^2 = 18%	Fixed-effect model	1.4	0.87, 2.27	0.17
Headache	7	46/2100	48/1625	= 0.63, I^2 = 0	Fixed-effect model	0.83	0.55, 1.24	0.36
Diarrhea	5	18/1855	13/1381	= 0.85, I^2 = 0	Fixed-effect model	1.3	0.65, 2.62	0.46
Nasopharyngitis	7	67/1445	52/1433	= 0.84, I^2 = 0	Fixed-effect model	1.3	0.89, 1.89	0.17
Edema	3	8/559	3/555	= 0.42, I^2 = 0	Fixed-effect model	2.25	0.69, 7.35	0.18
Upper respiratory tract infection	6	44/2303	28/1824	= 0.50, I^2 = 0	Fixed-effect model	1.22	0.75, 1.97	0.42
Cough	6	39/2043	13/1568	= 0.27, I^2 = 22%	Fixed-effect model	2.38	1.27, 4.47	0.007
Arthralgia	4	10/1425	10/953	= 0.40, I^2 = 0	Fixed-effect model	0.93	0.40, 2.18	0.87
Back pain	3	10/428	20/425	= 0.17, I^2 = 44%	Fixed-effect model	0.49	0.23, 1.05	0.07
Influenza	3	16/428	15/425	= 0.53, I^2 = 0	Fixed-effect model	1.07	0.52, 2.19	0.86
Hypotension	2	4/417	7/412	= 0.47, I^2 = 0	Fixed-effect model	0.56	0.16, 1.93	0.36
Dyspepsia	2	8/639	2/636	= 0.98, I^2 = 0	Fixed-effect model	4.05	0.86, 19.19	0.08
Hyperuricemia	2	38/1247	35/776	= 0.39, I^2 = 0	Fixed-effect model	0.71	0.44, 1.15	0.17
Abdominal pain	2	5/417	3/412	= 0.09, I^2 = 66%	Random-effect model	1.19	0.05, 27.98	0.91